T細胞淋巴瘤之概觀與近年來治療之發展

T-cell Lymphomas Overview and Recent Advances

張景明(Ching-Ming Chang) ； 吳仁光(Ren-Guang Wu)

《內科學誌》 27卷3期 (2016/06) Pp. 139-148

https://doi.org/10.6314/JIMT.2016.27(3).04

摘要

T細胞淋巴瘤佔所有非何杰金氏淋巴瘤約15%，是異質性很大的一種淋巴癌症，根據2008的WHO分類，有23個次分類，預後一般比B細胞淋巴瘤還要差。最早以CHOP處方為基礎的化學治療，成績並不理想，因此包括加強化療處方(增加劑量、加上藥物)、自體造血幹細胞移植當作鞏固性治療、異體造血幹細胞移植的救援性治療，在過去的研究都獲得些許進展。再者，近年來，一些新的化療藥物、組蛋白去乙醯酶抑制劑、抗體藥物複合體，甚至是最近幾年興起的免疫治療，在許多的臨床研究都獲得成功，相信將可為病人帶來更多治療上的進步，提升整體T細胞淋巴瘤的預後。

關鍵字

T細胞淋巴瘤 ； 造血幹細胞移植 ； 組蛋白去乙醯酶抑制劑 ； 抗體藥物複合體

並列摘要

T-cell lymphomas account for around 15% of all non-Hodgkin’s lymphomas and are a kinds of lymphoid malignancies with great heterogeneity. According to the 2008 WHO classification of lymphoid neoplasms, T-cell lymphomas have 23 subtypes. The prognosis of T cell lymphomas is worse than B-cell lymphomas. In the past, the outcome was poor using CHOP-based combinational chemotherapy. In previous time, enhanced chemotherapy regimens (increased dose intensity, dose dense, add-on medication), autologous hematopoietic stem cell transplant and allogeneic hematopoietic stem cell transplant all have some advances in T-cell lymphomas. Moreover, some new chemotherapy, histone deacetylase inhibitor, antibody-drug conjugate and immune checkpoint inhibitor all make some success in many clinical trials in recent years. We believe the outcome will be much better in T-cell lymphomas in the future.

並列關鍵字

T cell lymphoma ； Hematopoietic stem cell transplant ； Histone deacetylase inhibitor ； Antibody-drug conjugate